• 1
    Wilder RL. Neuroimmunoendocrinology of the rheumatic diseases: past, present, and future. Ann N Y Acad Sci 2002; 966: 139.
  • 2
    Masi AT, Aldag JC, Jacobs JW. Rheumatoid arthritis: neuroendocrine immune integrated physiopathogenetic perspectives and therapy. Rheum Dis Clin North Am 2005; 31: 13160.
  • 3
    Cutolo M, Straub RH, Bijlsma JW. Neuroendocrine-immune interactions in synovitis. Nat Clin Pract Rheumatol 2007; 3: 62734.
  • 4
    Holmdahl R, Carlsten H, Jansson L, Larsson P. Oestrogen is a potent immunomodulator of murine experimental rheumatoid disease. Br J Rheumatol 1989; 28(Suppl. 1): 548.
  • 5
    Straub RH. The complex role of estrogens in inflammation. Endocr Rev 2007; 28: 52174.
  • 6
    Levine JD, Collier DH, Basbaum AI, Moskowitz MA, Helms CA. Hypothesis: the nervous system may contribute to the pathophysiology of rheumatoid arthritis. J Rheumatol 1985; 12: 40611.
  • 7
    Schaffler A, Muller-Ladner U, Scholmerich J, Buchler C. Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev 2006; 27: 44967.
  • 8
    Straub RH, Besedovsky HO. Integrated evolutionary, immunological, and neuroendocrine framework for the pathogenesis of chronic disabling inflammatory diseases. FASEB J 2003; 17: 217683.
  • 9
    Straub RH, Del Rey A, Besedovsky HO. Emerging concepts for the pathogenesis of chronic disabling inflammatory diseases: neuroendocrine-immune interactions and evolutionary biology. In: AderR, ed. Psychoneuroimmunology. San Diego, CA: Elsevier – Academic Press, 2007; 21732.
  • 10
    Rassow J, Hauser K, Netzker R, Deutzmann R. Biochemistry. Stuttgart: Georg Thieme, 2008.
  • 11
    Rolfe DF, Brown GC. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiol Rev 1997; 77: 73158.
  • 12
    Blaxter K. Energy Metabolism in Animals and Man. Cambridge, New York, New Rochelle, Melbourne, Sydney: Cambridge University Press, 1989.
  • 13
    Lippert H. Lehrbuch Anatomie. Munich: Elsevier, 2003.
  • 14
    Princiotta MF, Finzi D, Qian SB et al. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 2003; 18: 34354.
  • 15
    Buttgereit F, Brand MD. A hierarchy of ATP-consuming processes in mammalian cells. Biochem J 1995; 312: 1637.
  • 16
    Schmid D, Burmester GR, Tripmacher R, Kuhnke A, Buttgereit F. Bioenergetics of human peripheral blood mononuclear cell metabolism in quiescent, activated, and glucocorticoid-treated states. Biosci Rep 2000; 20: 289302.
  • 17
    Kuhnke A, Burmester GR, Krauss S, Buttgereit F. Bioenergetics of immune cells to assess rheumatic disease activity and efficacy of glucocorticoid treatment. Ann Rheum Dis 2003; 62: 1339.
  • 18
    Calder PC. Fuel utilization by cells of the immune system. Proc Nutr Soc 1995; 54: 6582.
  • 19
    Maciver NJ, Jacobs SR, Wieman HL, Wofford JA, Coloff JL, Rathmell JC. Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J Leukoc Biol 2008; 84: 94957.
  • 20
    Iemitsu M, Itoh M, Fujimoto T et al. Whole-body energy mapping under physical exercise using positron emission tomography. Med Sci Sports Exerc 2000; 32: 206770.
  • 21
    Schedlowski M, Hosch W, Oberbeck R et al. Catecholamines modulate human NK cell circulation and function via spleen-independent beta 2-adrenergic mechanisms. J Immunol 1996; 156: 939.
  • 22
    Dhabhar FS, McEwen BS. Bidirectional effects of stress and glucocorticoid hormones on immune function: possible explanations for paradoxical observations. In: AderR, FeltenDL, CohenN, eds. Psychoneuroimmunology. San Diego: Academic Press, 2001; 30138.
  • 23
    Born J, Lange T, Hansen K, Molle M, Fehm HL. Effects of sleep and circadian rhythm on human circulating immune cells. J Immunol 1997; 158: 445464.
  • 24
    Lange T, Dimitrov S, Fehm HL, Westermann J, Born J. Shift of monocyte function toward cellular immunity during sleep. Arch Intern Med 2006; 166: 1695700.
  • 25
    Merl V, Peters A, Oltmanns KM et al. Preserved circadian rhythm of serum insulin concentration at low plasma glucose during fasting in lean and overweight humans. Metabolism 2004; 53: 144953.
  • 26
    Wildenhoff KE, Johansen JP, Karstoft H, Yde H, Sorensen NS. Diurnal variations in the concentrations of blood acetoacetate and 3-hydroxybutyrate. The ketone body peak around midnight and its relationship to free fatty acids, glycerol, insulin, growth hormone and glucose in serum and plasma. Acta Med Scand 1974; 195: 258.
  • 27
    Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 4656.
  • 28
    Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 1988; 12: 12337.
  • 29
    Preston BT, Capellini I, McNamara P, Barton RA, Nunn CL. Parasite resistance and the adaptive significance of sleep. BMC Evol Biol 2009; doi:10.1186/1471-2148-9-7.
  • 30
    Buttgereit F, Burmester GR, Brand MD. Bioenergetics of immune functions: fundamental and therapeutic aspects. Immunol Today 2000; 21: 1929.
  • 31
    Higami Y, Barger JL, Page GP et al. Energy restriction lowers the expression of genes linked to inflammation, the cytoskeleton, the extracellular matrix, and angiogenesis in mouse adipose tissue. J Nutr 2006; 136: 34352.
  • 32
    Okano K, Tsukazaki T, Ohtsuru A et al. Parathyroid hormone-related peptide in synovial fluid and disease activity of rheumatoid arthritis. Br J Rheumatol 1996; 35: 105662.
  • 33
    Feske S. Calcium signalling in lymphocyte activation and disease. Nat Rev Immunol 2007; 7: 690702.
  • 34
    Del Rey A, Roggero E, Randolf A et al. IL-1 resets glucose homeostasis at central levels. Proc Natl Acad Sci U S A 2006; 103: 1603944.
  • 35
    Takeda S, Elefteriou F, Levasseur R et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002; 111: 30517.
  • 36
    Rennie KL, Hughes J, Lang R, Jebb SA. Nutritional management of rheumatoid arthritis: a review of the evidence. J Hum Nutr Diet 2003; 16: 97109.
  • 37
    Van De Laar MA, Nieuwenhuis JM, Former-Boon M, Hulsing J, Van Der Korst JK. Nutritional habits of patients suffering from seropositive rheumatoid arthritis: a screening of 93 Dutch patients. Clin Rheumatol 1990; 9: 4838.
  • 38
    Hansen GV, Nielsen L, Kluger E et al. Nutritional status of Danish rheumatoid arthritis patients and effects of a diet adjusted in energy intake, fish-meal, and antioxidants. Scand J Rheumatol 1996; 25: 32530.
  • 39
    Lundberg AC, Akesson A, Akesson B. Dietary intake and nutritional status in patients with systemic sclerosis. Ann Rheum Dis 1992; 51: 11438.
  • 40
    Payne A. Nutrition and diet in the clinical management of multiple sclerosis. J Hum Nutr Diet 2001; 14: 34957.
  • 41
    Bacon MC, White PH, Raiten DJ et al. Nutritional status and growth in juvenile rheumatoid arthritis. Semin Arthritis Rheum 1990; 20: 97106.
  • 42
    Roubenoff R, Roubenoff RA, Cannon JG et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994; 93: 237986.
  • 43
    Owen OE, Reichard Jr GA, Patel MS, Boden G. Energy metabolism in feasting and fasting. Adv Exp Med Biol 1979; 111: 16988.
  • 44
    Liefmann R. Endocrine imbalance in rheumatoid arthritis and rheumatoid spondylitis; hyperglycemia unresponsiveness, insulin resistance, increased gluconeogenesis and mesenchymal tissue degeneration; preliminary report. Acta Med Scand 1949; 136: 22632.
  • 45
    Roubenoff R, Roubenoff RA, Ward LM, Stevens MB. Catabolic effects of high-dose corticosteroids persist despite therapeutic benefit in rheumatoid arthritis. Am J Clin Nutr 1990; 52: 11137.
  • 46
    Walsmith J, Roubenoff R. Cachexia in rheumatoid arthritis. Int J Cardiol 2002; 85: 8999.
  • 47
    Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 2006; 84: 146372.
  • 48
    Fong Y, Moldawer LL, Marano M et al. Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol 1989; 256: R65965.
  • 49
    Sarzi-Puttini P, Atzeni F, Scholmerich J, Cutolo M, Straub RH. Anti-TNF antibody therapy improves glucocorticoid- induced insulin-like growth factor-1 (IGF-1) resistance without influencing myoglobin and IGF-1 binding proteins 1 and 3. Ann Rheum Dis 2005; 65: 3015.
  • 50
    Masi AT, Josipovic DB, Jefferson WE. Low adrenal androgenic-anabolic steroids in women with rheumatoid arthritis (RA): gas-liquid chromatographic studies of RA patients and matched normal control women indicating decreased 11-deoxy-17-ketosteroid excretion. Semin Arthritis Rheum 1984; 14: 123.
  • 51
    Cutolo M, Balleari E, Giusti M, Monachesi M, Accardo S. Sex hormone status of male patients with rheumatoid arthritis: evidence of low serum concentrations of testosterone at baseline and after human chorionic gonadotropin stimulation. Arthritis Rheum 1988; 31: 13147.
  • 52
    Lahita RG, Bradlow HL, Ginzler E, Pang S, New M. Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 1987; 30: 2418.
  • 53
    Härle P, Pongratz G, Weidler C, Büttner R, Schölmerich J, Straub RH. Possible role of leptin in hypoandrogenicity in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 2004; 63: 80916.
  • 54
    Kaufmann J, Kielstein V, Kilian S, Stein G, Hein G. Relation between body mass index and radiological progression in patients with rheumatoid arthritis. J Rheumatol 2003; 30: 23505.
  • 55
    Escalante A, Haas RW, Del RI. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005; 165: 16249.
  • 56
    Van Der Helm-van Mil AH, Van Der Kooij SM, Allaart CF, Toes RE, Huizinga TW. A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis 2008; 67: 76974.
  • 57
    Westhoff G, Rau R, Zink A. Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum 2007; 56: 357582.
  • 58
    Svenson KL, Lundqvist G, Wide L, Hallgren R. Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones. Metabolism 1987; 36: 9403.
  • 59
    Paolisso G, Valentini G, Giugliano D et al. Evidence for peripheral impaired glucose handling in patients with connective tissue diseases. Metabolism 1991; 40: 9027.
  • 60
    Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 2002; 4: R5.
  • 61
    Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006; 54: 276575.
  • 62
    Erdem H, Dinc A, Pay S, Simsek I, Turan M. Peripheral insulin resistance in patients with Behcet’s disease. J Eur Acad Dermatol Venereol 2006; 20: 3915.
  • 63
    Chung CP, Avalos I, Oeser A et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007; 66: 20814.
  • 64
    Bregenzer N, Hartmann A, Strauch U, Scholmerich J, Andus T, Bollheimer LC. Increased insulin resistance and beta cell activity in patients with Crohn’s disease. Inflamm Bowel Dis 2006; 12: 536.
  • 65
    La MG, Cacciapuoti F, Buono R et al. Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diab Vasc Dis Res 2007; 4: 1305.
  • 66
    Babu NP, Bobby Z, Selvaraj N, Harish BN. Increased fructosamine in non-diabetic rheumatoid arthritis patients: role of lipid peroxides and glutathione. Clin Chem Lab Med 2006; 44: 84852.
  • 67
    Rodriguez-Garcia J, Requena JR, Rodriguez-Segade S. Increased concentrations of serum pentosidine in rheumatoid arthritis. Clin Chem 1998; 44: 2505.
  • 68
    Lakatos J, Harsagyi A. Serum total, HDL, LDL cholesterol, and triglyceride levels in patients with rheumatoid arthritis. Clin Biochem 1988; 21: 936.
  • 69
    Bruderlein H, Daniel R, Boismenu D, Julien N, Couture F. Fatty acid profiles of serum phospholipids in patients suffering rheumatoid arthritis. Prog Lipid Res 1981; 20: 62531.
  • 70
    Iannello S, Cavaleri A, Milazzo P, Cantarella S, Belfiore F. Low fasting serum triglyceride level as a precocious marker of autoimmune disorders. MedGenMed 2003; 5: 20.
  • 71
    Rossner S, Lofmark C. Dyslipoproteinaemia in patients with active, chronic polyarthritis. A study on serum lipoproteins and triglyceride clearance (intravenous fat tolerance test). Atherosclerosis 1977; 28: 4152.
  • 72
    Cauza E, Cauza K, Hanusch-Enserer U, Etemad M, Dunky A, Kostner K. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 2002; 114: 10047.
  • 73
    Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008; 118: 29923002.
  • 74
    Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 6658.
  • 75
    Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005; 64: 7656.
  • 76
    Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 836.
  • 77
    Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 77283.
  • 78
    Frauwirth KA, Thompson CB. Regulation of T lymphocyte metabolism. J Immunol 2004; 172: 46615.
  • 79
    Calder PC, Dimitriadis G, Newsholme P. Glucose metabolism in lymphoid and inflammatory cells and tissues. Curr Opin Clin Nutr Metab Care 2007; 10: 53140.
  • 80
    Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 122536.
  • 81
    Ilowite NT, Samuel P, Ginzler E, Jacobson MS. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988; 31: 85963.
  • 82
    Ettinger Jr WH, Hazzard WR. Elevated apolipoprotein-B levels in corticosteroid-treated patients with systemic lupus erythematosus. J Clin Endocrinol Metab 1988; 67: 4258.
  • 83
    Borba EF, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997; 6: 5339.
  • 84
    Jones SM, Harris CP, Lloyd J, Stirling CA, Reckless JP, McHugh NJ. Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis 2000; 59: 9049.
  • 85
    Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007; 28: 6975.
  • 86
    Grunfeld C, Feingold KR. Tumor necrosis factor, cytokines, and the hyperlipidemia of infection. Trends Endocrinol Metab 1991; 2: 2139.
  • 87
    Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei III E, Kufe DW. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol 1988; 6: 34450.
  • 88
    Khovidhunkit W, Kim MS, Memon RA et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004; 45: 116996.
  • 89
    Pond CM, Mattacks CA. Interactions between adipose tissue around lymph nodes and lymphoid cells in vitro. J Lipid Res 1995; 36: 221931.
  • 90
    Pond CM. Paracrine relationships between adipose and lymphoid tissues: implications for the mechanism of HIV-associated adipose redistribution syndrome. Trends Immunol 2003; 24: 138.
  • 91
    Jessop DS, Harbuz MS. A defect in cortisol production in rheumatoid arthritis: why are we still looking? Rheumatology (Oxford) 2005; 44: 1097100.
  • 92
    Straub RH, Paimela L, Peltomaa R, Schölmerich J, Leirisalo-Repo M. Inadequately low serum levels of steroid hormones in relation to IL-6 and TNF in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheum 2002; 46: 65462.
  • 93
    Dekkers JC, Geenen R, Godaert GL et al. Experimentally challenged reactivity of the hypothalamic pituitary adrenal axis in patients with recently diagnosed rheumatoid arthritis. J Rheumatol 2001; 28: 1496504.
  • 94
    Miller AH, Pariante CM, Pearce BD. Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Adv Exp Med Biol 1999; 461: 10716.
  • 95
    Webster JC, Oakley RH, Jewell CM, Cidlowski JA. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci U S A 2001; 98: 686570.
  • 96
    Djurhuus CB, Gravholt CH, Nielsen S, Pedersen SB, Moller N, Schmitz O. Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans. Am J Physiol Endocrinol Metab 2004; 286: E48894.
  • 97
    Castagnetta LA, Carruba G, Granata OM et al. Increased estrogen formation and estrogen to androgen ratio in the synovial fluid of patients with rheumatoid arthritis. J Rheumatol 2003; 30: 2597605.
  • 98
    Schmidt M, Weidler C, Naumann H, Schölmerich J, Straub RH. Androgen conversion in osteoarthritis and rheumatoid arthritis synoviocytes – androstenedione and testosterone inhibit estrogen formation and favor production of more potent 5alpha-reduced androgens. Arthritis Res Ther 2005; 7: R93848.
  • 99
    Pedersen SB, Kristensen K, Hermann PA, Katzenellenbogen JA, Richelsen B. Estrogen controls lipolysis by up-regulating alpha2A-adrenergic receptors directly in human adipose tissue through the estrogen receptor alpha. Implications for the female fat distribution. J Clin Endocrinol Metab 2004; 89: 186978.
  • 100
    Elbers JM, Asscheman H, Seidell JC, Gooren LJ. Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. Am J Physiol 1999; 276: E31725.
  • 101
    Perry F, Heller PH, Kamiya J, Levine JD. Altered autonomic function in patients with arthritis or with chronic myofascial pain. Pain 1989; 39: 7784.
  • 102
    Kuis W, Jong-de Vos V, Sinnema G et al. The autonomic nervous system and the immune system in juvenile rheumatoid arthritis. Brain Behav Immun 1996; 10: 38798.
  • 103
    Nakajima A, Sendo W, Tsutsumino M et al. Acute sympathetic hyperfunction in overlapping syndromes of systemic lupus erythematosus and polymyositis. J Rheumatol 1998; 25: 163841.
  • 104
    Glück T, Oertel M, Reber T, Zietz B, Schölmerich J, Straub RH. Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus. I. The hypothalamus-autonomic nervous system axis. J Rheumatol 2000; 27: 90310.
  • 105
    Härle P, Straub RH, Wiest R et al. Increase of sympathetic outflow measured by NPY and decrease of the hypothalamic–pituitary–adrenal axis tone in patients with SLE and RA – another example of uncoupling of response systems. Ann Rheum Dis 2005; 65: 516.
  • 106
    Dekkers JC, Geenen R, Godaert GL, Bijlsma JW, Doornen LJP. Sympathetic and parasympathetic nervous system activity at night in patients with recently diagnosed rheumatoid arthritis. In: DekkersJC, ed. Thesis: Psychophysiological Responsiveness in Recently Diagnosed Patients with Rheumatoid Arthritis. Dordrecht: Dekkers, 2003; 5574.
  • 107
    Dekkers JC, Geenen R, Godaert GL, Bijlsma JW, Van Doornen LJ. Elevated sympathetic nervous system activity in patients with recently diagnosed rheumatoid arthritis with active disease. Clin Exp Rheumatol 2004; 22: 6370.
  • 108
    Scherrer U, Sartori C. Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 1997; 96: 410413.
  • 109
    Levine JD, Dardick SJ, Roizen MF, Helms C, Basbaum AI. Contribution of sensory afferents and sympathetic efferents to joint injury in experimental arthritis. J Neurosci 1986; 6: 34239.
  • 110
    Härle P, Mobius D, Carr DJ, Schölmerich J, Straub RH. An opposing time-dependent immune-modulating effect of the sympathetic nervous system conferred by altering the cytokine profile in the local lymph nodes and spleen of mice with type II collagen-induced arthritis. Arthritis Rheum 2005; 52: 130513.
  • 111
    Straub RH, Grum F, Strauch UG et al. Anti-inflammatory role of sympathetic nerves in chronic intestinal inflammation. Gut 2008; 57: 91121.
  • 112
    Capellino S, Falk W, Straub RH. Reserpine as a new therapeutical agent in arthritis. Arthritis Rheum 2009; 58: S730.
  • 113
    Miller LE, Jüsten HP, Schölmerich J, Straub RH. The loss of sympathetic nerve fibers in the synovial tissue of patients with rheumatoid arthritis is accompanied by increased norepinephrine release from synovial macrophages. FASEB J 2000; 14: 2097107.
  • 114
    Del Rey A, Wolff C, Wildmann J et al. Disrupted joint-immune-brain communication during experimental arthritis. Arthritis Rheum 2008; 58: 30909.
  • 115
    Straub RH, Rauch L, Fassold A, Lowin T, Pongratz G. Neuronally released sympathetic neurotransmitters stimulate splenic interferon-gamma secretion from T cells in early type II collagen-induced arthritis. Arthritis Rheum 2008; 58: 345060.
  • 116
    Lorton D, Lubahn C, Sweeney S et al. Differences in the injury/sprouting response of splenic noradrenergic nerves in Lewis rats with adjuvant-induced arthritis compared with rats treated with 6-hydroxydopamine. Brain Behav Immun 2009; 23: 27685.
  • 117
    Moore MC, Satake S, Baranowski B, Hsieh PS, Neal DW, Cherrington AD. Effect of hepatic denervation on peripheral insulin sensitivity in conscious dogs. Am J Physiol Endocrinol Metab 2002; 282: E28696.
  • 118
    Vatamaniuk MZ, Horyn OV, Vatamaniuk OK, Doliba NM. Acetylcholine affects rat liver metabolism via type 3 muscarinic receptors in hepatocytes. Life Sci 2003; 72: 187182.
  • 119
    Xue C, Aspelund G, Sritharan KC, Wang JP, Slezak LA, Andersen DK. Isolated hepatic cholinergic denervation impairs glucose and glycogen metabolism. J Surg Res 2000; 90: 1925.
  • 120
    Bartness TJ, Song CK. Thematic review series: adipocyte biology. Sympathetic and sensory innervation of white adipose tissue. J Lipid Res 2007; 48: 165572.
  • 121
    Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 2007; 117: 28996.
  • 122
    Waldburger JM, Boyle DL, Pavlov VA, Tracey KJ, Firestein GS. Acetylcholine regulation of synoviocyte cytokine expression by the alpha7 nicotinic receptor. Arthritis Rheum 2008; 58: 343949.
  • 123
    Van Maanen MA, Lebre MC, Van Der PT et al. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis Rheum 2009; 60: 11422.
  • 124
    Bertero MT, Caligaris-Cappio F. Anemia of chronic disorders in systemic autoimmune diseases. Haematologica 1997; 82: 37581.
  • 125
    Kötter I, Wacker A, Koch S et al. Anakinra in patients with treatment-resistant adult-onset Still’s disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum 2007; 37: 18997.
  • 126
    Nicolas G, Bennoun M, Devaux I et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 2001; 98: 87805.
  • 127
    Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 2001; 131: 568S79S.
  • 128
    Marx JJ. Iron and infection: competition between host and microbes for a precious element. Best Pract Res Clin Haematol 2002; 15: 41126.
  • 129
    Theurl I, Fritsche G, Ludwiczek S, Garimorth K, Bellmann-Weiler R, Weiss G. The macrophage: a cellular factory at the interphase between iron and immunity for the control of infections. Biometals 2005; 18: 35967.
  • 130
    Hibbert JM, Creary MS, Gee BE, Buchanan ID, Quarshie A, Hsu LL. Erythropoiesis and myocardial energy requirements contribute to the hypermetabolism of childhood sickle cell anemia. J Pediatr Gastroenterol Nutr 2006; 43: 6807.
  • 131
    Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002; 51: 234854.
  • 132
    Wasserman DH, Lavina H, Lickley A, Vranic M. Effect of hematocrit reduction on hormonal and metabolic responses to exercise. J Appl Physiol 1985; 58: 125762.
  • 133
    Walsh NC, Crotti TN, Goldring SR, Gravallese EM. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005; 208: 22851.
  • 134
    Al-Awadhi A, Olusi S, Al-Zaid N, Prabha K. Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis. J Rheumatol 1999; 26: 12506.
  • 135
    Lange U, Jung O, Teichmann J, Neeck G. Relationship between disease activity and serum levels of vitamin D metabolites and parathyroid hormone in ankylosing spondylitis. Osteoporos Int 2001; 12: 10315.
  • 136
    Thomas T, Burguera B, Melton III LJ et al. Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 2001; 29: 11420.
  • 137
    Lee NK, Karsenty G. Reciprocal regulation of bone and energy metabolism. Trends Endocrinol Metab 2008; 19: 1616.
  • 138
    Li YP, Stashenko P. Proinflammatory cytokines tumor necrosis factor-alpha and IL-6, but not IL-1, down-regulate the osteocalcin gene promoter. J Immunol 1992; 148: 78894.
  • 139
    Duncan H. Osteoporosis in rheumatoid arthritis and corticosteroid induced osteoporosis. Orthop Clin North Am 1972; 3: 57183.
  • 140
    Takeda S, Karsenty G. Molecular bases of the sympathetic regulation of bone mass. Bone 2008; 42: 83740.
  • 141
    Selye H, Fortier C. Adaptive reactions to stress. Res Publ Assoc Res Nerv Ment Dis 1949; 29: 318.
  • 142
    Kohm AP, Sanders VM. Norepinephrine: a messenger from the brain to the immune system. Immunol Today 2000; 21: 53942.